Overview

Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy, The A.C.T Study

Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
To assess the safety of intravitreal aflibercept injection in the treatment of proliferative diabetic retinopathy (PDR) by evaluating the incidence and severity of adverse events.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Ophthalmic Consultants of Long Island
Collaborator:
Regeneron Pharmaceuticals
Treatments:
Aflibercept